Who are Drospirenone Ethinyl estradiol Myo-inositol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drospirenone-ethinyl-estradiol-myo-inositol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Drospirenone Ethinyl estradiol Myo-inositol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drospirenone Ethinyl estradiol Myo-inositol (Drospirenone Ethinyl estradiol Myo-inositol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive with insulin sensitizer. Area: Gynecology / Reproductive Health.

marketed Oral contraceptive with insulin sensitizer Progesterone receptor, estrogen receptor, inositol signaling pathway Gynecology / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

Drospirenone Ethinyl estradiol Myo-inositol (Drospirenone Ethinyl estradiol Myo-inositol) — AGUNCO Obstetrics and Gynecology Centre. This combination oral contraceptive suppresses ovulation through progestin and estrogen activity while myo-inositol may improve insulin sensitivity and metabolic parameters.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drospirenone Ethinyl estradiol Myo-inositol TARGET	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive with insulin sensitizer class)

AGUNCO Obstetrics and Gynecology Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drospirenone Ethinyl estradiol Myo-inositol — Competitive Intelligence Brief. https://druglandscape.com/ci/drospirenone-ethinyl-estradiol-myo-inositol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab